DBV TECHNOLOGIE/S (NASDAQ:DBVT)’s stock price fell 7.7% during trading on Monday . The company traded as low as $8.13 and last traded at $8.22, 843,588 shares traded hands during trading. An increase of 196% from the average session volume of 285,425 shares. The stock had previously closed at $8.91.
A number of research firms have commented on DBVT. Goldman Sachs Group began coverage on DBV TECHNOLOGIE/S in a research note on Monday, June 17th. They set a “buy” rating and a $14.00 price target on the stock. BidaskClub upgraded DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 15th. Zacks Investment Research cut DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, ValuEngine upgraded DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $14.81.
The business has a 50-day moving average price of $9.27 and a two-hundred day moving average price of $9.14. The firm has a market cap of $499.45 million, a PE ratio of -2.42 and a beta of 1.80.
DBV TECHNOLOGIE/S Company Profile (NASDAQ:DBVT)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.